Overview
Cue Health built a connected testing system around a reusable reader, disposable cartridges, and a mobile application. Ayub Khattak and Clint Sever began the company in 2010, after the H1N1 outbreak exposed the difficulty of obtaining timely diagnostic information. COVID-19 later created a large market for its technology.[1][2]
The company filed Chapter 7 petitions on May 28, 2024. Its decline combined a sharp revenue contraction with product and regulatory problems. Earlier authorization and strong emergency demand did not remove the need for sustained sales, controlled product changes, and dependable support.[3][8]
Image 1 / 1
Founding Story
Khattak described the 2009 H1N1 outbreak as the starting problem. People seeking one piece of diagnostic information had to navigate clinics or emergency rooms. He met Sever, a product designer and neighbor in Santa Monica, while they were finishing school. Their work then required years of development before a broad commercial opportunity emerged.[1]
The date needs care: the outbreak supplied the inspiration in 2009, while the company and partner accounts use 2010 for its beginning. Treating the pandemic-era sales surge as the company's start would erase that preceding research period.[1][2]
Khattak described the ambition as improving “healthcare information access.” He said, “We set about bringing together and creating the right technologies that would solve the problem.” These statements describe the founding goal, without establishing the later products’ effectiveness.[2]
The original ambition extended beyond one infection. The platform concept connected a test performed near the patient with software and care. That wider vision required additional validated tests and commercial adoption; a reusable reader alone did not create a complete diagnostic menu.[3]
Timeline
- 2010: Cue's development history began after the H1N1 outbreak.[1]
- June 2020: FDA issued emergency authorization for a professional-use COVID-19 test.[6]
- March 2021: A separate emergency authorization covered the home and over-the-counter test.[6]
- September 2021: Cue priced an offering of 12.5 million shares at $16, representing $200 million gross before fees and an optional extra allocation.[4]
- June 6, 2023: FDA granted De Novo marketing authorization for the Cue COVID-19 Molecular Test through its traditional review process.[5]
- May 2024: FDA issued a warning letter and told users not to use the two emergency-authorized tests.[6][7]
- May 28, 2024: Cue announced Chapter 7 wind-down petitions.[8]
- October 9, 2024: FDA revoked the two emergency-use authorizations at Cue's request.[9]
What They Built
A sample wand, cartridge, reader, and application formed the testing experience. The reader processed the cartridge, and software delivered the result. Google Cloud's case study describes work to expand the company's cloud infrastructure as manufacturing and deployment accelerated. This was a connected service as well as a physical device.[2]
Cue's annual report describes a broader planned platform with diagnostics, data, consumer and clinician applications, and care integrations. Those layers could help an installed reader support repeated use. They also created dependencies across consumables, software availability, clinical workflows, and commercial partners.[3]
Authorization applied to particular products and conditions. The June 2023 traditional authorization was a real regulatory milestone. It must remain distinct from the two emergency-authorized products in the later warning and revocation notices. The evidence does not support rewriting Cue's entire history as a product that never received authorization.[5][6]
Market Position
Target Customers
Cue sold into organizations that needed repeated testing and also pursued individual home users. The first-person 2022 account identifies business demand as central to its growth. The consumer offer required customers to obtain a reader and keep buying cartridges, making repeated need and affordability relevant to retention.[1]
Market Size
The financial record shows how quickly realized demand changed. Total revenue was $618.107 million in 2021, $483.476 million in 2022, and $70.936 million in 2023. These are annual company revenues in US dollars, including product and grant or other revenue. They are not financing totals or estimates of all diagnostic spending.[3]
A large emergency market did not establish the same purchasing pattern after testing requirements changed. The useful planning question was how much recurring revenue the company could support beyond that exceptional period.
Competition
Cue's promise combined convenient testing with molecular methods. Customers could also use laboratories or other authorized testing products. The value depended on the specific test, use setting, result quality, price, and access. The reviewed sources do not establish that one format was uniformly superior across every situation.
Business Model
A reusable reader could support continued cartridge purchases and a wider service relationship. That creates a potential recurring model, but only if customers continue testing and the required products remain available. An installed device is an opportunity for later transactions, rather than proof of future revenue.
The priced IPO represented an important capital event. Its $200 million gross figure described that offering before costs and optional shares. It should not be presented as total company financing, a valuation, or operating revenue.[4]
Product changes also carry commercial consequences. FDA's May 9 warning letter identified changes made without the required authorization and concerns about performance and stability. The letter requested that distribution stop pending concurrence. This was a specific documented finding about modified devices, beyond a general statement that regulation is difficult.[6]
Outcome and evolution
The revenue decline preceded the final May 2024 warning and bankruptcy. It therefore cannot be explained entirely by that last regulatory action. Quality and authorization problems nevertheless weakened an already strained business. The company said attempts to secure financing or a strategic transaction did not produce a viable alternative to wind-down.[3][8]
FDA's updated safety notice records a Class II recall and revocation of the two emergency-use authorizations in October 2024. The Federal Register notice says Cue had stopped manufacturing, shipping, and distributing the affected products. Supporting revocation material also described the required mobile application as disabled. These events concern the end of the original system's practical service path.[7][9]
The trustee-appointed auctioneer announced laboratory and manufacturing-equipment auctions in August 2024, covering more than 2,000 lots. The reviewed announcement establishes the disposal process, without establishing final proceeds or a buyer continuing the complete reader-and-test service.[10]
This review did not establish a continuing original operation, a complete commercial successor, final creditor distributions, or the disposition of every intellectual-property asset. It also does not quantify how much of the failure arose from demand, cost structure, or product changes.
Key Lessons
- Separate emergency demand from a durable purchasing pattern.
- Keep product changes inside the authorization and validation process that applies to the specific device.
- Plan continuity for cartridges, applications, and support together.
- Measure new test adoption before treating an installed reader base as a broader platform business.
Sources
- Founder origin and business interview
- Google Cloud partner case study
- 2023 annual financial statements
- 2021 IPO pricing announcement
- FDA traditional authorization announcement
- FDA warning letter
- FDA current safety communication
- Company Chapter7 announcement
- Federal Register revocation notice
- Trustee-appointed auctioneer asset notice